Olsovská V, Siprová H, Beránek M, Soska V
II. interní klinika Lékarské fakulty MU a FN u sv. Anny, Brno.
Vnitr Lek. 2005 Dec;51(12):1356-64.
A syndrome of growth hormone deficiency in adults (GHDA) is a syndrome characterised by metabolic deviations, body composition abnormalities, fatigue, decreased quality of life and some cardiovascular changes. The aim of the study was to assess the influence of the growth hormone (GH) replacement therapy on body composition, bone changes, serum lipids levels and some parameters of sugar metabolism in the course of 7-year monitoring. We followed 34 individuals of mean age of 41.73 +/- 2.49 years (mean +/- SE). Severe deficiency of GH was demonstrated by performing stimulation insulin tolerance test. Duration of treatment was 4.13 +/- 0.36 years (mean +/- SE). Patients were examined before the initiation of replacement therapy, after 6 months and further in yearly visits. To determine a statistical level of significance in individual parameters we compared initial baseline status (before drug administration) with the status in individual time intervals. The body composition was examined by anthropometric methods, bioelectric impedance and by densitometry, bone changes were examined by means of DEXA. There were no statistically significant changes of weight, but the waist circumference significantly decreased (p < 0.05), as well as the sum of skinfold thickness (p < 0.05) within the whole treatment period. The percentage of body fat mass measured by the BIA method was significantly changed after the period of 3 years (p < 0.05). Upon the densitometrical measurement of the body composition a significant decrease in kilograms of body fat mass (FM) occurred in the first year of the treatment (p < 0.05) and an increase in lean body mass (LBM) in kilograms during our complete monitoring (p < 0.05). A statistically significant increase in bone density was found in the whole-body BMD and BMC after the first year of the treatment. In the examination of peripheral bone changes a statistically significant increase in BMD occurred (expressed as a Z score) in the area of proximal femur after the first year and collum femoris after three years (p < 0.05), there was a significant increase in BMD of the lumbar spine already after one year of the treatment (p < 0.05) and changes were significant also in further four years. There were found no statistically significant changes related to the sugar metabolism. In the field of lipid metabolism a decrease of total and LDL cholesterol occurred already after a half of the year of the treatment (p < 0.05), changes were significant also in further four years. HDL cholesterol levels have had a progressive tendency, but they were not statistically significant. Positive changes of body composition, an increase in bone density and a decrease of total and LDL cholesterol were demonstrated in the course of the growth hormone replacement therapy.
成人生长激素缺乏综合征(GHDA)是一种以代谢偏差、身体成分异常、疲劳、生活质量下降以及一些心血管变化为特征的综合征。本研究的目的是评估在7年的监测过程中,生长激素(GH)替代疗法对身体成分、骨骼变化、血脂水平和糖代谢的一些参数的影响。我们跟踪了34名平均年龄为41.73±2.49岁(平均值±标准误)的个体。通过进行胰岛素耐量刺激试验证实存在严重的GH缺乏。治疗持续时间为4.13±0.36年(平均值±标准误)。在开始替代治疗前、6个月后以及随后每年进行一次检查。为了确定各个参数的统计学显著性水平,我们将初始基线状态(给药前)与各个时间间隔的状态进行了比较。通过人体测量方法、生物电阻抗和密度测定法检查身体成分,通过双能X线吸收法(DEXA)检查骨骼变化。体重没有统计学上的显著变化,但在整个治疗期间,腰围显著减小(p<0.05),皮褶厚度总和也显著减小(p<0.05)。采用生物电阻抗分析法(BIA)测量的身体脂肪质量百分比在3年后有显著变化(p<0.05)。在对身体成分进行密度测定时,治疗第一年身体脂肪质量(FM)以千克计显著下降(p<0.05),在我们的整个监测期间,瘦体重(LBM)以千克计有所增加(p<0.05)。治疗第一年全身骨密度(BMD)和骨矿含量(BMC)有统计学上的显著增加。在外周骨变化检查中,治疗第一年股骨近端区域的BMD(以Z评分表示)有统计学上的显著增加,三年后股骨颈区域也有增加(p<0.05),治疗一年后腰脊柱的BMD就有显著增加(p<0.05),并且在接下来的四年中变化也很显著。未发现与糖代谢相关的统计学显著变化。在脂质代谢方面,治疗半年后总胆固醇和低密度脂蛋白胆固醇就有所下降(p<0.05),在接下来的四年中变化也很显著。高密度脂蛋白胆固醇水平有逐渐上升的趋势,但无统计学显著性。生长激素替代治疗过程中显示出身体成分的积极变化、骨密度增加以及总胆固醇和低密度脂蛋白胆固醇下降。